Targeted drug combination for HER2-positive breast cancer with brain metastases
Part of Cancer, Skin clinical trials.
This trial tests a new combination of targeted drugs for HER2-positive breast cancer that has spread to the brain. You might be able to join if you have brain metastases and are either newly diagnosed or have had prior brain radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older and able to give informed consent.
- You have metastatic breast cancer that is HER2-positive (a type of breast cancer that has too much HER2 protein, often tested by biopsy).
- You have brain metastases (cancer spread to the brain) that can be seen on MRI or CT scan, with at least one measurable brain tumor.
- Your physical condition is reasonably good (ECOG score 0–2), and your doctor expects you to live at least 3 more months.
- Your heart, blood, liver, and kidney function must be within acceptable levels, checked by blood tests and heart scans.
- If you are able to have children, you must have a negative pregnancy test and use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.